ArticleEndocrine2025
Clinical efficacy of radioactive iodine therapy in multifocal papillary thyroid microcarcinoma: a tertiary center experience.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decision-making value of a 1-cm tumor diameter cut-off for postoperativeAmerican journal of translational research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn recent years, the increased incidence of differentiated thyroid cancers has largely been attributed to microcarcinomas. The aim of this study was to evaluate the impact of adjuvant radioactive iodine (RAI) therapy on recurrence in patients with multifocal papillary thyroid carcinoma (PTC) ≤ 1 cm.
methodsA total of 74 patients who were >18 years of age and diagnosed with multifocal PTC ≤ 1 cm at a tertiary referral center between July 2015 and December 2023 were retrospectively evaluated.
resultsOf the 74 patients, 78.4% were female and 21.6% were male. The mean patient age was 45.6 ± 12.6 years, mean follow-up duration was 29.1 ± 22.8 months. Twenty two patients (29.7%) did not receive RAI [RAI (-)], whereas 52 patients (70.3%) received [RAI (+)]. Recurrence was observed in 6.7% (5/74) of patients. Four of the five recurrences occurred in patients initially managed without RAI. The recurrence rate was significantly higher in the RAI (-) group (18.2%, n = 4) compared to the RAI (+) group (1.9%, n = 1) (p = 0.011). Patients without recurrence had a mean age of 46.8 ± 12.0 years, whereas those with recurrence had a mean age of 28.6 ± 8.7 years. The mean age of patients with recurrence was significantly lower (p < 0.01).
conclusionRAI ablation appears to improve disease-free survival in multifocal PTC ≤ 1 cm. These findings suggest that RAI therapy decisions in multifocal PTC ≤ 1 cm should be individualized based on tumor variant, invasion characteristics, and patient age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.